Factory 99% Canagliflozin Powder CAS 842133-18-0 Chemical Intermediate Canagliflozin

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A821
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Canagliflozin
• CAS: 842133-18-0
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Canagliflozin
Appearance	White Powder
CAS NO.	842133-18-0
Storage	Keep in a cool, dry, dark location

 

Canagliflozin is an orally available, selective inhibitor of sodium-glucose cotransporter 2 (SGLT2). It belongs to a class of medications used to treat diabetes by lowering blood glucose levels.

 

1. Type 2 Diabetes Management: Canagliflozin is primarily indicated for the treatment of type 2 diabetes mellitus in adults.
2. Combination Therapy: It may be used as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, thiazolidinediones, or improve glycemic control.
3. Cardiovascular and Renal Protection: Beyond glycemic control, Canagliflozin has also demonstrated benefits in reducing the risk of cardiovascular events and preserving renal function in patients with type 2 diabetes.

1. SGLT2 Inhibition: Canagliflozin works by inhibiting the SGLT2 transporter in the proximal tubules of the kidneys, which reduces the reabsorption of glucose from the filtrate and increases its excretion in the urine.
2. Blood Glucose Lowering: This mechanism of action leads to a decrease in blood glucose levels, thereby aiding in the management of type 2 diabetes.
3. Extra-glycemic Benefits: In addition to its glycemic effects, Canagliflozin has been shown to have favorable effects on cardiovascular and renal outcomes, potentially reducing the risk of heart attack, stroke, and the progression of diabetic kidney disease.